Supplementary Protection Certificates

Patentability of pharmaceutical inventions
European Patent Academy ● Munich ● 10 November 2017

Pierre Véron
Honorary President EPLAW (European Patent Lawyers Association)
Member of the Expert Panel group of the Unified Patent Court
Member of the Drafting Committee of the Rules of Procedure

1

Contents

1. Why a supplementary protection for pharmaceutical products?
2. EU Regulation on SPCs for medicinal products, plant protection products and paediatric extension of SPC
3. Formal conditions for obtaining an SPC
4. Substantive conditions for obtaining an SPC
   a) *the product is protected by a basic patent in force;*
   b) *a valid authorisation to place the product on the market as a medicinal product has been granted;*
   c) *the product has not already been the subject of a certificate;*
   d) *the authorisation referred to in point (b) is the first authorisation to place the product on the market as a medicinal product*
5. Scope of the SPC
6. Duration of the SPC

2

Overview

Supplementary Protection Certificate

- SPCs are a unique (*sui generis*) intellectual property right that constitute an extension (of up to 5 years) to the term of a patent right (of 20 years)
- SPCs apply to innovative pharmaceutical and plant protection products that have been protected by a patent and authorized by regulatory authorities
- They aim to offset the loss of effective patent protection that occurs due to the compulsory and lengthy testing and clinical trials that such products require prior to obtaining regulatory marketing approval

3

1. Why a supplementary protection for pharmaceutical products?

- Supplementary Protection Certificates were introduced in Europe to encourage innovation by compensating for the long time needed to obtain regulatory approvals (marketing authorization) for medicaments
- Available in the US and Japan as "Patent Term Extension"

4

Supplementary Protection Certificates

Patent life: the law



Patent protection lasts 20 years

* more precisely: 01/01/2020 00:00:00

5

Supplementary Protection Certificates

Patent life: the economics mechanics, telecom, etc.





6

Supplementary Protection Certificates

Patent life: the economics pharma without SPC



7

Supplementary Protection Certificates

Patent life: the economics pharma with SPC



8

Supplementary Protection Certificates

Patent life: the economics pharma with SPC + Paediatric Extension of the SPC



9

Supplementary Protection Certificates

Paramount $ importance of SPC



80% of the sales of the anti-depressor Prozac in the UK have been made after the patent expiry

10

Hot off the press

Supplementary Protection Certificates

Paramount $ importance of SPC

1. This is a patent action. It relates to EP (UK) 0 888 289. The patent covers an anti-epileptic drug called lacosamide. The lacosamide compound is (R) -N-benzyl-2-acetoamido-3-methoxypropionamide. Lacosamide is a successful medicine, with annual worldwide sales projected for next year to reach €1 billion. The patent application was filed on 17th March 1997 claiming priority from a US filing on 15th March 1996. The patent expired on 18th March 2017. There is a supplementary protection certificate (SPC/GB09/007) which means that protection for lacosamide in this jurisdiction continues until 2022.

2. The claimant (Accord) is a generic pharmaceutical company. It contends that the patent is invalid. If it is right then the SPC will be revoked, clearing the way for generic competition. The defendant (RCT) is a technology investment and

Judgment handed down on 7 November 2017 by the English Patents Court about the epileptic drug lacosamide Vimpat® (Accord Healthcare v. RCT)

11

Supplementary Protection Certificates

2. EU regulations on SPCs

- Regulation (EC) № 469/2009 (codifying Regulation 1768/92) is a **EU Regulation**

- But the SPCs are **granted nationally** by the national patent offices (DE SPC, FR SPC, NL SPC, UK SPC, etc.): one application for each Member State where an SPC is requested

12

Supplementary Protection Certificates

The possible future creation of a European SPC title?

12 October 2017

EU Commission launches a Public consultation on supplementary protection certificates (SPCs) and patent research exemptions
https://ec.europa.eu/info/consultations/public-consultation-supplementary-protection-certificates-spcs-and-patent-research-exemptions_en

- the creation of a European SPC title (Unitary SPC)
- an update of the scope of EU patent research exemptions
- the introduction of an SPC "manufacturing waiver" (manufacturing for export outside the EU)

13

Supplementary Protection Certificates

Article 2 Regulation (EC) № 469/2009

"***Any product protected by a patent*** *in the territory of a Member State and* ***subject, prior to being placed on the market as a medicinal product, to an administrative authorization procedure*** *as laid down in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (2) or Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (3)* ***may****, under the terms and conditions provided for in this Regulation,* ***be the subject of a certificate***."

14

Supplementary Protection Certificates

Regulation (EEC) № 1610/96 concerning SPC for plant protection products

- Recital (13):

  « *(13) Whereas the certificate confers the same rights as those conferred by the basic patent; whereas, consequently, where the basic patent covers an active substance and its various derivatives (salts and esters),* ***the certificate confers the same protection****;* »

- Recital (17):

  « *(17) Whereas the detailed rules in recitals (…), 13 (…) of this Regulation are also valid, mutatis mutandis, for the interpretation in particular of (…) Article 4 (…) of Council Regulation (EEC) № 1768/92.* »

15

Supplementary Protection Certificates

Paediatric extension of SPCs

The duration of the SPC can, however, be extended to 5 years **plus 6 months** when the SPC relates to a human medicinal product for which data from clinical trials conducted in accordance with an agreed Paediatric Investigation Plan (PIP) have been submitted

(Article 36 of Regulation (EC) № 1901/2006).

16

SPC prerequisites

- A patent

- A drug with a marketing authorization

17

SPC legal framework



18

SPC: a complex legal area



+ 5 cases pending

19

3. Formal conditions for obtaining an SPC

- Who can file?
- When to file?
- Where to file?

20

Supplementary Protection Certificates

Who can file the SPC?

Article 6 **Entitlement to the certificate**

- *"The certificate shall be granted to the holder of the basic patent or his successor in title".*
- Patent holder vs. Marketing Authorization holder?

  When the basic patent and the Marketing Authorization are held by different entities, the patent proprietor may apply without the consent of the Marketing Authorization holder CJEU Case C-181/95, 23/01/97, **Biogen** / Smithkline]

21

Supplementary Protection Certificates

When the SPC application should be filed?

Article 7 **Application for a certificate**

"*The application for a certificate shall be lodged within six months of the date on which the authorization referred to in Article 3(b) to place the product on the market as a medicinal product was granted*".

22

When the SPC application should be filed?

The Liechtenstein case

"*In so far as an authorisation to place a medicinal product on the market issued by the Swiss authorities and automatically recognised by the Principality of Liechtenstein under that State's legislation is* ***the first authorisation to place that product on the market in one of the States of the European Economic Area****, it constitutes the first authorisation to place the product on the market within the meaning of Article 13 of Council Regulation (EEC) № 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products, as it is to be read for the purposes of the application of the Agreement on the European Economic Area*"

CJEU Case C-181/95, 21/04/2005, **Novartis** C-207/03 and C-252/03

23

Where the SPC application should be filed?

- One application for each Member State where an SPC is requested; the SPC applications must be filed in the respective national patent offices:
  - Deutsches Patent- und Markenamt for DE SPC
  - United Kingdom Intellectual Property Office for UK SPC
  - Institut National de la propriété industrielle for FR SPC
  - Octrooicentrum Nederland for NL SPC…
- No European SPC (Unitary SPC) at the moment (work in progress; public consultation launched 12 October 2017 by EU Commission)

24

4. Substantive conditions for obtaining an SPC

Regulation (EC) № 469/2009
Article 3 Conditions for obtaining a certificate

a) the product is protected by a basic patent in force;

b) a valid authorisation to place the product on the market as a medicinal product has been granted;

c) the product has not already been the subject of a certificate;

d) the authorisation referred to in point (b) is the first authorisation to place the product on the market as a medicinal product.

25

Medicinal products

- Drugs
- Vaccines
- Diagnosis products acting *in vivo* (no SPC for product acting *in vitro*)
- Medical device: SPC not available except when the medical device includes a medicinal product (e.g. a stent coated with a drug)

26

Supplementary Protection Certificates

The product must be "protected" by the basic patent

Article 3 a) of Regulation № 469/2009

"*the product is protected by a basic patent in force within the meaning of Article 3 a)*"

27

Supplementary Protection Certificates

Which product can be designated in the SPC?

Article 1 b) of Regulation № 469/2009:

- The active ingredient of the drug
- The combination of active ingredients of the drug
- More?

28

Supplementary Protection Certificates

Article 3(a)

The product is "protected" in any of the forms covered by the basic patent

"*where a product in the form referred to in the marketing authorization is protected by a basic patent in force, the supplementary protection certificate is capable of covering the product, as a medicinal product, in* ***any of the forms enjoying the protection of the basic patent****.*

2. In order to determine, in connection with the application of Regulation № 1768/92 and, in particular, Article 3(a) thereof, whether a product is protected by a basic patent, reference must be made to the rules which govern that patent."

CJEU Case C-392/97, 16/09/1999, **Farmitalia** Carlo Erba (Idarubicin)

29

Supplementary Protection Certificates

Combination products

The "Disclosure Test" vs the "Infringement Test"

1. The "Disclosure Test":

The combination must be **disclosed or identifiable** in the basic patent
(GB, FR , DE, SE)

2. The "Infringement Test"

The combination must **infringe** the patent pursuant to Article 69 EPC
(CH, NO, CZ)

30

Combination products

Medeva C-322/10

Basic patent

Method claim for the preparation of an acellular *B. pertussis* vaccine

Marketing Authorization

Multi-vaccine against:

- Whooping cough
- Diphtheria
- Tetanus
- Polio
- Meningitis



31

Combination products

The Medeva test

*"1. the competent industrial property office of a Member State (may **not** grant) a supplementary protection certificate relating to active ingredients which are **not specified in the wording of the claims** of the basic patent relied on in support of the application for such a certificate.*

*2. the competent industrial property office of a Member State (may grant) a supplementary protection certificate for a combination of two active ingredients, corresponding to that **specified in the wording of the claims** of the basic patent relied on, where the medicinal product for which the marketing authorization is submitted in support of the application for a supplementary protection certificate contains not only that combination of the two active ingredients **but also other active ingredients**."*

CJEU Case C-322/10, 24/11/2011, **Medeva**

32

Tenofovir (Gilead's drug Truvada®)

- Preliminary injunction denied in DK and FR because the SPC's combination of tenofovir disoproxil (as fumarate) and emtricitabine was not "*protected by the basic patent*",
- SPC held valid in CH: the Swiss court refused to adopt the CJEU's "Medeva" line of decisions. As a consequence, Swiss SPCs will be assessed based on the infringement test. No additional criteria, such as "*specified in the wording of the claims*" (Medeva), "*the claims relate, implicitly but necessarily …*" (Eli Lilly), "*core inventive advance …*" (Actavis) or the like are to be applied.

33

Regulation (EC) № 469/2009 Article 3

Further conditions for obtaining a certificate

a) the product is protected by a basic patent in force;

b) a valid authorisation to place the product on the market as a medicinal product has been granted;

c) the product has not already been the subject of a certificate;

d) the authorisation referred to in point (b) is the first authorization to place the product on the market as a medicinal product.

34

5. Scope of the SPC



Scope of protection
Practical questions

Is an SPC designating the active ingredient A infringed by:

- a drug containing A + B?
- a drug containing A’ (a variant of A)?

Scope of protection
Legal question

Is the scope of an SPC designating the active ingredient A:

- limited to the drugs having A as active ingredient?
- or comparable to the scope of a patent claiming A?

37

Scope of protection
Regulation № 469/2009

- Article 4, « *Subject-matter of protection* »:

  « *Within the limits of the protection conferred by the basic patent, the protection conferred by a certificate shall extend only to the product covered by the authorization to place the corresponding medicinal product on the market and for any use of the product as a medicinal product that has been authorized before the expiry of the certificate.* »

- Article 5, « *Effects of the certificate* »:

  « *Subject to the provisions of Article 4, the certificate shall confer the* ***same rights as conferred by the basic patent*** *and shall be subject to the same limitations and the same obligations.* »

38

Scope of protection: combination products

"where a 'product' consisting of an active ingredient was protected by a basic patent and the holder of that patent was able to rely on the protection conferred by that patent for that 'product' in order to oppose the marketing of a medicinal product containing that active ingredient in combination with one or more other active ingredients,
***a supplementary protection certificate** granted for that 'product' **enables its holder**, after the basic patent has expired, **to oppose the marketing by a third party of a medicinal product containing that product for a use of the 'product'**, as a medicinal product, which was authorized before that certificate expired."*

C-442/11, 09/02/2012 **Novartis** AG v Actavis UK Ltd

39

6. Duration of SPCs

Art 13 states that the duration of an SPC is:

"... equal to the period which elapsed between

- *the date on which the application for a basic patent was lodged and*
- *the date of the first authorisation to place the product on the market in the Community*
- *reduced by a period of five years"*

40

Duration of SPCs

- The maximum duration of the SPC is 5 years (+ 6 months if paediatric extension applies)
- The SPC covers every medical use of the product authorized before its expiration

41

Duration of SPCs



42

Paediatric extension

Consequences of the 6-month SPC extension include:

- the maximum term of an SPC can be up to 5 years **and 6 months**; and
- the maximum duration of market exclusivity (patent + SPC) can be up to 15 years **and 6 months**.
- An extension of an SPC can only be awarded if there is an SPC to extend; as an SPC only has a positive term if more than 5 years have elapsed between patent filing and marketing authorization issuance, this causes the so called "negative duration" scenario when the marketing authorization has been granted less that 5 years after the patent application date

43

"Negative duration" SPCs for a paediatric extension



"the period which elapsed between the date on which the application for a basic patent was lodged (01/01/2000) and the date of the first authorization to place the product on the market in the Community (01/01/2004)
reduced by a period of five years"

44

The Merck decision accepts "*negative duration*" SPC

"*… **medicinal products can be the object of the grant of a supplementary protection certificate where the period** that has elapsed between the date of lodging the basic patent application and the first marketing authorization in the European Union **is less than five years**. In such a case, the period of the paediatric extension provided for by the latter regulation starts to run from the date determined by deducting from the patent expiry date the difference between five years and the duration of the period which elapsed between the lodging of the patent application and the grant of the first marketing authorization*"

Case C-125/10, 8 December 2011, **Merck Sharp & Dohme**

45

Pierre Véron

pierre.veron@veron.com

Thank you